Scholarlink

<p>Non steroidal anti-inflammatory drugs (NSAIDs) are widely used for analgesic and anti-inflammatory purposes but are often hampered by side effects such as gastrointestinal issues. Flurbiprofen, a potent NSAID, has significant therapeutic potential but may cause adverse effects due to its non-selective cyclooxygenase (COX) inhibition. This study aimed to enhance its efficacy and reduce side effects by developing flurbiprofen-loaded ZIF-8 nanoparticles (FP@ZIF-8). ZIF-8, with its high porosity, pH sensitivity, and biocompatibility, serves as an excellent carrier for targeted drug delivery. FP@ZIF-8 nanoparticles demonstrated successful flurbiprofen encapsulation with a drug loading rate of up to 53% and showed pH-responsive drug release. In vitro studies revealed that FP@ZIF-8 nanoparticles not only promoted the proliferation of human umbilical vein endothelial cells (HUVECs) but also significantly reduced lipopolysaccharide (LPS) -induced reactive oxygen species (ROS) production in RAW264.7 macrophages. In vivo experiments further indicated that FP@ZIF-8 effectively alleviated inflammation-induced pain in mouse models and downregulated key inflammatory cytokines. The biosafety assessment confirmed the excellent biocompatibility and safety of FP@ZIF-8 nanoparticles. These findings suggest that FP@ZIF-8 is a promising drug delivery system for treating inflammatory pain conditions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Flurbiprofen@ZIF-8 nanoformulation with potential for analgesia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月2日

查看全文
  • Peng Pan,
  • Sixv Ding,
  • Wang Yang,
  • Yibo Wang,
  • Hua Qian,
  • Ayang Zhao,
  • Wengang Ding

摘要

Non steroidal anti-inflammatory drugs (NSAIDs) are widely used for analgesic and anti-inflammatory purposes but are often hampered by side effects such as gastrointestinal issues. Flurbiprofen, a potent NSAID, has significant therapeutic potential but may cause adverse effects due to its non-selective cyclooxygenase (COX) inhibition. This study aimed to enhance its efficacy and reduce side effects by developing flurbiprofen-loaded ZIF-8 nanoparticles (FP@ZIF-8). ZIF-8, with its high porosity, pH sensitivity, and biocompatibility, serves as an excellent carrier for targeted drug delivery. FP@ZIF-8 nanoparticles demonstrated successful flurbiprofen encapsulation with a drug loading rate of up to 53% and showed pH-responsive drug release. In vitro studies revealed that FP@ZIF-8 nanoparticles not only promoted the proliferation of human umbilical vein endothelial cells (HUVECs) but also significantly reduced lipopolysaccharide (LPS) -induced reactive oxygen species (ROS) production in RAW264.7 macrophages. In vivo experiments further indicated that FP@ZIF-8 effectively alleviated inflammation-induced pain in mouse models and downregulated key inflammatory cytokines. The biosafety assessment confirmed the excellent biocompatibility and safety of FP@ZIF-8 nanoparticles. These findings suggest that FP@ZIF-8 is a promising drug delivery system for treating inflammatory pain conditions.